A citation-based method for searching scientific literature


List of co-cited articles
553 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
12

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
11

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
10

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.
Emma Ahlqvist, Petter Storm, Annemari Käräjämäki, Mats Martinell, Mozhgan Dorkhan, Annelie Carlsson, Petter Vikman, Rashmi B Prasad, Dina Mansour Aly, Peter Almgren,[...]. Lancet Diabetes Endocrinol 2018
685
10

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E Kahn, Steven M Haffner, Mark A Heise, William H Herman, Rury R Holman, Nigel P Jones, Barbara G Kravitz, John M Lachin, M Colleen O'Neill, Bernard Zinman,[...]. N Engl J Med 2006
9


Type 2 diabetes mellitus.
Ralph A DeFronzo, Ele Ferrannini, Leif Groop, Robert R Henry, William H Herman, Jens Juul Holst, Frank B Hu, C Ronald Kahn, Itamar Raz, Gerald I Shulman,[...]. Nat Rev Dis Primers 2015
566
9

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
9

Mechanisms linking obesity to insulin resistance and type 2 diabetes.
Steven E Kahn, Rebecca L Hull, Kristina M Utzschneider. Nature 2006
8


Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
Michael E J Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie, Carl Peters, Sviatlana Zhyzhneuskaya, Ahmad Al-Mrabeh, Kieren G Hollingsworth,[...]. Lancet Diabetes Endocrinol 2019
220
7

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
891
7


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
6

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
570
6

Type 2 diabetes.
Sudesna Chatterjee, Kamlesh Khunti, Melanie J Davies. Lancet 2017
770
6

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
6

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
6

Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents.
Domenico Tricò, Andrea Natali, Silva Arslanian, Andrea Mari, Ele Ferrannini. JCI Insight 2018
50
12

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
5

Accurate assessment of beta-cell function: the hyperbolic correction.
Richard N Bergman, Marilyn Ader, Katrin Huecking, Gregg Van Citters. Diabetes 2002
390
5



Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
5

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
I M Stratton, A I Adler, H A Neil, D R Matthews, S E Manley, C A Cull, D Hadden, R C Turner, R R Holman. BMJ 2000
5

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
Michael Ej Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie, Carl Peters, Sviatlana Zhyzhneuskaya, Ahmad Al-Mrabeh, Kieren G Hollingsworth,[...]. Lancet 2018
599
5

Glucolipotoxicity: fuel excess and beta-cell dysfunction.
Vincent Poitout, R Paul Robertson. Endocr Rev 2008
709
5




Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.
S E Kahn, R L Prigeon, D K McCulloch, E J Boyko, R N Bergman, M W Schwartz, J L Neifing, W K Ward, J C Beard, J P Palmer. Diabetes 1993
5

Pancreatic beta-cell mass in European subjects with type 2 diabetes.
J Rahier, Y Guiot, R M Goebbels, C Sempoux, J C Henquin. Diabetes Obes Metab 2008
510
5


Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
5

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
378
5

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study.
Muhammad A Abdul-Ghani, Christopher P Jenkinson, Dawn K Richardson, Devjit Tripathy, Ralph A DeFronzo. Diabetes 2006
362
4


Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
234
4

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.
Stanley S Schwartz, Solomon Epstein, Barbara E Corkey, Struan F A Grant, James R Gavin, Richard B Aguilar. Diabetes Care 2016
144
4



Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery.
Roy Taylor, Ahmad Al-Mrabeh, Sviatlana Zhyzhneuskaya, Carl Peters, Alison C Barnes, Benjamin S Aribisala, Kieren G Hollingsworth, John C Mathers, Naveed Sattar, Michael E J Lean. Cell Metab 2018
127
4

Effect of an Intensive Lifestyle Intervention on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Mette Yun Johansen, Christopher Scott MacDonald, Katrine Bagge Hansen, Kristian Karstoft, Robin Christensen, Maria Pedersen, Louise Seier Hansen, Morten Zacho, Anne-Sophie Wedell-Neergaard, Signe Tellerup Nielsen,[...]. JAMA 2017
80
5


A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
Sangeeta Kashyap, Renata Belfort, Amalia Gastaldelli, Thongchai Pratipanawatr, Rachele Berria, Wilailak Pratipanawatr, Mandeep Bajaj, Lawrence Mandarino, Ralph DeFronzo, Kenneth Cusi. Diabetes 2003
343
4

The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
Ralph A DeFronzo, Devjit Tripathy, Muhammad Abdul-Ghani, Nicolas Musi, Amalia Gastaldelli. J Clin Endocrinol Metab 2014
23
17

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.
Ele Ferrannini, Amalia Gastaldelli, Yoshinori Miyazaki, Masafumi Matsuda, Andrea Mari, Ralph A DeFronzo. J Clin Endocrinol Metab 2005
361
4

Splanchnic and renal metabolism of insulin in human subjects: a dose-response study.
E Ferrannini, J Wahren, O K Faber, P Felig, C Binder, R A DeFronzo. Am J Physiol 1983
219
4

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
293
4



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.